Our team members have a wide variety of interests reflecting their diverse of backgrounds covering clinical and experimental pharmacology, neurology, neuropsychology, health services research, evidence synthesis, statistics and medical sociology. Research teams, comprising postgraduate students, post-doctoral scientists, and clinical trainees, conduct independent studies in their specific fields of expertise. In addition, group members routinely work together on cognate projects, contributing to a large overall portfolio of world-leading research.
Our research addresses some of the most significant issues in epilepsy therapeutics, including investigation of the molecular mechanisms of epilepsy and its response to drug treatment, genomics and pharmacogenomics of epilepsy, measuring and prognostic modelling of treatment outcomes in clinical epilepsy trials, contemporary neuroimaging, and study of the long-term psychological and psychosocial consequences of epilepsy and its treatment.
Some of our major current projects include:
CLAHRC NWC - a major NIHR initiative that is working to accelerate the translation of research findings into health service improvements.
Cochrane Epilepsy Group - the Cochrane group coordinates preparation & dissemination of systematic reviews of randomised controlled trials in epilepsy.
EPI4K - a global project exploring the genetic basis of epilepsy and its response to treatment.
EpiPGX - a Europe-wide pharmacogenomic study of efficacy, tolerability and safety of antiepileptic drugs.
NASH - a UK-wide audit of seizure management in hospitals.
NWHTMR - an MRC-NIHR partnership project aimed at developing new and improved approaches for the design, conduct and analysis of clinical trials.
SANAD-II - a UK-wide randomised comparative trial of the effectiveness, and cost effectiveness, of standard and new antiepileptic drugs.